Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Tag: PublicHealth

Home PublicHealth
NICE's Stroke Treatment Update: Tenecteplase to Improve Patient Care and Cut Costs
Post

Cost-Effective Stroke Treatment: NICE Recommends Tenecteplase Over Alteplase

Adults suffering from acute ischemic stroke are advised to consider tenecteplase as a therapy option by the National Institute for Health and Care Excellence (NICE). This choice represents a major advancement in the treatment of strokes and may have a big effect on patient care and NHS budget. Boehringer Ingelheim’s Tenecteplase, also marketed under the...

The Spread of Tick-Borne Illnesses: A Silent Epidemic in Canada
Post

Rising Tick-Borne Diseases in Canada: A Growing Public Health Concern

In Canada, tick-borne diseases are becoming more common. This presents a growing risk to public health and begs the question of whether the country’s current surveillance and public awareness initiatives are adequate to handle this expanding issue. In addition to the more well-known Lyme disease, other illnesses including anaplasmosis, babesiosis, and Powassan virus are also...

New Hope in HIV Prevention: Biannual Injections Versus Daily Pill
Post

Revolutionizing HIV Prevention: The Promise of Lenacapavir Injections

The daily use of a pill such as Truvada has been a mainstay of the fight against HIV infections for over a decade. This kind of preventive medication, called pre-exposure prophylaxis, or PrEP, has demonstrated impressive efficacy in clinical trials, with up to 99% success rate in preventing new HIV infections that are contracted through...

Dengue Danger: Public Health Concerns Mount Ahead of Paris Olympic
Post

Paris Olympics: A Looming Threat of Dengue Fever Outbreaks

Health experts are growing increasingly concerned about the possibility of a “super-spreader event” as France gets ready to welcome millions of tourists this summer. Mark Booth, a senior lecturer in parasite epidemiology at Newcastle University, is one prominent figure who has raised concerns about the impending Paris Olympics. There is a serious chance that the...

"NIH's Lenacapavir Trials Set to Transform HIV Prevention for Women and Injecting Drug Users"
Post

New NIH Trials Aim to Address HIV Inequities in Women and Intravenous Drug Users

On Tuesday, the National Institutes of Health (NIH) declared the commencement of two noteworthy clinical trials that are intended to assess the efficacy and safety of an HIV pre-exposure prophylaxis (PrEP) medication among marginalized demographic groups. This effort, which focuses on groups like women and intravenous drug users that have previously been underrepresented in clinical...

Genetic Engineering Triumph: Djibouti Deploys GMO Mosquitoes to Curb Malaria Threat
Post

Innovative Approach: Djibouti Launches ‘Friendly Mosquito Programme’ to Tackle Malaria Crisis

On May 23, 2024, genetically modified (GMO) mosquitoes were released in Djibouti, East Africa, as part of a ground-breaking initiative to fight malaria. This important event, which took place in the Djiboutian city suburb of Ambouli, is the result of a cooperative pilot project between Oxitec Ltd., the Djibouti government, and the well-known non-governmental organization...